MHRA Drug Safety Update – March 2018

MHRA Drug Safety Update – March 2018

March 12, 2018

Date Issued: 8th March 2018

A new Medicines and Healthcare products Regulatory Agency (MHRA) Drug Safety Update (Vol 11, Issue 8, March 2018) has been published and includes articles on:

  • daclizumab (Zinbryta▼): suspension and recall for safety reasons; review patients as soon as possible and start alternative therapy;
  • Esmya (ulipristal acetate) for uterine fibroids: do not initiate or re-start treatment; monitor liver function in current and recent users; and
  • head lice eradication products: risk of serious burns if treated hair is exposed to open flames or other sources of ignition, for example, cigarettes.

To see the latest MHRA Drug Safety Update in full, visit the GOV.uk website.



Posted in:


More Latest News >

October 2018 Category M prices

Category M reimbursement prices for October 2018 can be found here. These show a net overall reduction compared to July 2018...

PSNC CEO webinar now on-demand

Community pharmacy contractors can now access an online recording of PSNC’s recent CEO webinar. Almost 500 people registered for yesterday’s...

Ask PSNC: Flu FAQs

The team at PSNC has received a number of queries on the NHS Flu Vaccination Service 2018/19. Below are some...